United StatesAUPH▲
Aurinia settles Lupkynis patent litigation with Teva
Aurinia Pharmaceuticals has settled patent litigation with Teva Pharmaceutical Industries over Lupkynis, delaying any generic version of the drug until December 7, 2036, at the earliest. Teva had filed an Abbreviated New Drug Application to sell generic voclosporin, the active ingredient in Lupkynis. Aurinia still faces patent litigation against several other generic companies seeking to market generic voclosporin.
AUPH · Regulation · Positive Settlement with Teva delays generic Lupkynis until 2036, protecting Aurinia's market exclusivity.
TEVA · Regulation · Negative Teva agreed to delay its generic voclosporin launch until December 2036, blocking its planned generic entry.